The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

It is unknown if the cardioprotective and renal effects of glucagon‐like peptide‐1 receptor agonists are consistent across blood pressure (BP) categories in patients with type 2 diabetes and at high risk of cardiovascular events. Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patient...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetes Obes Metab
Main Authors: Leiter, Lawrence A., Bain, Stephen C., Bhatt, Deepak L., Buse, John B., Mazer, C. David, Pratley, Richard E., Rasmussen, Søren, Ripa, Maria Sejersten, Vrazic, Hrvoje, Verma, Subodh
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2020
Assuntos:
Brief Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7496251/
https://ncbi.nlm.nih.gov/pubmed/32372454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14079
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares